Sixteen grand in total...........

I can't be mad at that;nice indeed.

It's going to be sad to see you go so soon but I guess it's all for the best.

Don't be a stranger.

Who knows;you may want back in at a later date and you'd be welcomed then too.

I first thought it was a bold move;to introduce Probuphine at the symposium but in hindsight they are simply conducting business as usual.

They didn't set the scheduling date although there's something to be said for timing.

Don't be discouraged.

Today's low is 1.91 and we're holding around 1.97 now.

Possibly some short-sighted individuals but i'm thinking also those holding the stock for quite a while,eagerly waiting to either break even or make a profit(possibly the result of a run-up).

Warren Buffet poaches 4 senior AIG executives.

Ok.....you drew attention but 4 people doesn't a company make.

In retrospect,you may have done the company a favor.

I'm sure there are many experienced individuals,who were patiently waiting for their opportunity to shine.

The thing here is that everyone;even senior executives have someone to answer to.........those "higher up" are still there

I can envision "exciting and new" on the horizon.

.
The New AIG...Better Than Ever.

April 17,2013


Michael Schmidt of Leerink Swann said he thinks Zogenix's ZoHydro is approvable, potentially with a modified REMS.

"We believe ZGNX shares are already pricing in the worst case scenario. Thus, we believe FDA approval would be a significant positive surprise, and even a CRL calling for modification to the proposed REMS program would also be a positive for ZGNX shares, in our view," said Schmidt.

In addition, Schmidt thinks the FDA is required to maintain a level playing field.

"FDA were to decide to not approve Zohydro due to its high abuse potential, we think FDA would also need to pull all other non-abuse deterrent opiates from the market,” suggested the analyst.

Leerink Swann has an Outperform rating on Zogenix, Inc.

I could see a lot of people wanting to get in just before the weekend.

This way they won't have to worry about those that will do their due diligence over the weekend;eagerly awaiting Monday's open.

I wonder if any FDA members will be in attendance at tomorrow's symposium.
If so,a last minute presentation could do wonders towards a positive decision.

I'm sure the presentation is going to be fine tuned,with any unanswered questions explained in depth.

It would be interesting if during the presentation(either am or pm session),news was to surface of an approval.

Anything's possible at this point.

To be honest with you,it could be a myriad of reasons.

Indecision,rationalization,overanalyzing......just to name a few.

Possibilities are endless.

Tomorrow's another day.

We'll see how things pan out then.

From Investopedia:

Definition of 'Confidential Treatment Order - CTO'
An order that provides confidential treatment for certain documents and information, that a company would otherwise have to file. A confidential treatment order (CTO) is issued by the Securities and Exchange Commission (SEC) and may only be in effect for a certain period of time, rather than indefinitely.

Companies would typically seek a CTO in order to keep information that would otherwise put it at a disadvantage, a secret. For example, a company may apply for such an order to keep information regarding a pricing arrangement made with a partner, secret, since competitors finding out this information may go after the partner with a more competitive price.
--------------------------------------------------------------------------------------
I believe that people are now beginning to see the potential.

Spot on.

I just contacted Fannie Mae's Investor Relations and was told that the Q1 2013 results will be out "on or by May 10th."

Nice.

Those who are loyal will reap the spoils......

Not so fast.

It just represents a selloff and isn't indicative of the entire day.

Correction:

The commercial goes: "I don't trade like others;I trade like me."

While we may have different styles and reasons for investing in particular stocks,the commonality lies with the vision of future potential in this company.

Just my assumption:

People are trying to save $$$ and are finding that Six Flags is the proximal choice.

The passes,new rides and overall atmosphere may be just what the "doctor" ordered.

Hello Rentier.

I'm loving your post and couldn't agree more with you.

To those posting me privately,it is never a bother when a fellow shareholder voices their opinion.

I share my 13 picks with the public at large because it's who I am.

Why hoard and keep to myself?

For those that bought in at a higher price than it is now,don't give up;not now anyway.

At least(the very least) wait until the FDA provides their announcement.

The powers that be.

I fully respect that you got in at an inopportune time and may be frustrated but this doesn't mean that the company isn't closer than ever towards commercialization.

A lot is happening and the collaboration of government scientists to bring this to commercialization,at this point in time,is quite intriguing.

You're welcome.

I read your message and have to say that you're right.
This is one of the reasons they say this is a high risk/high reward potential venture.

The inexperienced will get caught up and there are those that are betting on it happening.

It's a shame how many get caught up in this.

I could've gotten out at the high 1.90's but that wasn't my purpose.

I saw the pps rise and with it my balance in this particular stock.

There are no regrets for me,as i'm a "long-hauler" here.

When the dust clears and the manipulators with it,i'll still be around.

I see potential....what does that commercial say? "I don't trade like others;U trade like me."

At this point,I really can't blame you.

Someone or a few people purchased large and then shorted the stock.

You know what they say about kharma.

We have to take into account that there are those who got caught up in the last "run-up" and it can tend to make many skeptical. The saying "once bitten,twice shy" comes to mind.

I was weighing the advantages/disadvantages of a person investing now,as compared to the day before or even upon news of Probuphine's approval(I remain optimistic).

If the stock begins to gain momentum again,it may alert some.
There probably is a price that people have in mind;it will dictate when to invest going forward.

I am not for manipulative games of trickery but to a certain point it is allowed.

It's then I have to remind myself that this is not my "playground"....I was just allowed to play in it.

Steady as she goes.

I'm sort of glad that the Seeking Alpha article came out.
it seems to be quieting some potential stormy activity.

As the symposium,with respect to Probuphine will be this Friday in two parts(morning and afternoon), I realistically can't call it.There may be many at the convention that will try to get in that Friday(after the 1st session) or the latest Monday(that could be quite interesting).

For all we know,the results could be revealed on any given day now.
I like this because it provides the true investor with time to purchase and keeps things substantially "iffy" for the shorters;even though they tend to find a way into the logistics.

If the FDA waits until the 30th to release information,I anticipate over 2 (maybe 2.25 to 2.50)......stranger things have happened.

I'm just thinking out loud here but I can envision the possibility of people getting their "feet wet" in this stock,or the market in general and the greater momentum of the pps,the more they'd be willing to invest.
Small increments that increase with satisfactory results.

Thanks jmbar2.

Kudos to Sean Dunne for raising funds and getting this film both completed and entered into the festival.

I agree;another positive argument for Probuphine.

Addiction is real;tragically.

I pray the FDA is aware of films like this.

I reluctantly admit this but I am truly moved by what this documentary says;speaking to the epidemic at large while also addressing the humane aspect of lives being affected.

I believe that the primary focus is transparent glass but once the scientists brainstorm and share proprietary information,things can get rather interesting.

Hello MMcNeil and welcome.

I believe things will have a way of working themselves out.

Quick money is never my intention,when considering a stock and as I keep the focus on myself,I am ever so reminded that I shouldn't hate the player but rather the game developed.

I hate neither,as I believe there will be more than enough to go around.

Long money is strong money and short money is sport money.

American International Group Inc. (AIG) won dismissal of a whistle-blower lawsuit by a California couple who claimed the insurer defrauded the U.S. government by making false claims to secure its federal bailout in 2008.

U.S. District Judge Gonzalo Curiel in San Diego in an April 19 ruling dismissed the False Claims Act complaint by Derek and Nancy Casady because their allegations were based on publicly disclosed information and because they failed to provide enough factual information about AIG’s alleged scheme to support their fraud claims.

“After detailing facts regarding the government issued loans to AIG, and AIG’s history leading up to the loans, the Casadys merely allege that these actions ‘constitute fraud,’” the judge said. They “fail to provide any facts that these statements were actually false or that the government’s reliance on the false statements resulted in the subsequent loans.”

The U.S. government in 2011 declined to participate in the lawsuit. Curiel allowed the Casadys to file a second amended complaint to address the deficiencies.

James Mahon, a lawyer for the Casadys, didn’t immediately return a call to his office after regular business hours seeking comment on the ruling.

The case is U.S. ex rel Derek Casady v. American International Group Inc., 10-00431, U.S. District Court, Southern District of California (San Diego).
--------------------------------------------------------------------------------------
The stockholders respond to the news!

Hello kei and welcome.

It looks like the classic bears trying to take over the bulls annoyance.

I believe the bulls will win in the long run;more stamina.

Plus,it's too early to detect a winner, as the war (final outcome) is greater than the sum of its battles (volatility).

Titan Pharma Approaches Expected FDA Approval from Seeking Alpha
Apr 23 2013, 03:26 | about: TTNP.OB


We're seeing some new interest in Titan Pharmaceuticals (TTNP.OB) ahead of its PDUFA goal date of April 30th, 2013 for flagship drug Probuphine®. Bulls are expecting an FDA approval in line with the advisory committee vote that was held a month ago, which yielded an overall positive vote of 10-4-1 (10 in favor, 4 against, and 1 abstain) for approval of the Probuphine NDA that the company submitted in 2012.

Those who aren't familiar with Probuphine should note that the "drug" itself is actually a formulation of buprenorphine that is built into a subdermal implant (or "rod") which releases the active ingredient into the bloodstream over time. Probuphine is designed to provide a controlled, continuous dose of buprenorphine to opioid addicts for 6-12 months. Ideally, the implanted rod would not only improve compliance amongst recovering opioid addicts, but would prevent other forms of misuse.

The initial reaction to the preliminary adcom documents suggested that the vote could have turned against Titan's NDA due to the FDA's concerns with inadequate dosing for Probuphine-taking patients. In the phase III trials that reached completion in 2011, patients in the Probuphine arms were given 4 implants against the buprenorphine (Suboxone) arms.

The issue with Probuphine's dosing was never really dismissed (and remains an issue), although it was later argued that an overwhelming need for abuse deterrents (particularly for opioid addiction) was a bigger issue and supported an FDA approval with a REMS. The panel ultimately voted 10-5 in favor of the efficacy of Probuphine, and 12-2 (with one abstention) in favor of the safety profile of the implant.

Although there are dosage nitpicks that could result in an complete response letter (even with the REMS), many Titan Pharma supporters are making the "big picture" argument that the availability of alternatives to pills (like Suboxone) is a very important tool in the fight against opioid addiction. Subdermal implants like Probuphine allow patients to receive their medication for an extended period of time without much thought, and also provide much higher barriers for abuse relative to crush-resistant pills.

In a recent Wall Street Journal article, the huge threat of generic OxyContin was discussed in light of the huge surge of opioid abuse that we've seen throughout the last few years in the United States. We can also see the upward demand for opioid addiction treatments when analyzing the success of Suboxone, which is a standard-of-care formulation of buprenorphine and naloxone that was used as a control in Probuphine's clinical trials.

Suboxone generated $1.7 billion in 2012 on roughly 7.7 million prescriptions, which represents over 300% revenue growth from the product since 2008. With the introduction of generic OxyContin onto the market, we may see a further rise in opioid abuse from this alone if Purdue fails to convince the FDA to extend the date of its patent expiration.

As always, it's not certain whether or not the FDA will follow the advice of the advisory committee. The general opinion in the market seems to be that the FDA is more eager to win its fight against opioid addiction in the United States than to win its fight against the questionable dosing of Probuphine. Offering a subdermal implant that has been proven to be very safe in large clinical trials and will be approved under a REMS seems to be a very favorable bet, which is why the market is leaning towards an approval on the PDUFA goal date of April 30th, 2013 (assuming no extension due to tweaking of the REMS).

On the other hand, the market is not that confident on Probuphine's commercial success. TTNP would likely be trading 200-300% of its current value if the market believed that Probuphine could generate even one tenth of the revenue that Suboxone does.

The product still has dosage issues and may not be practical for most of the physicians treating opioid addiction. Adding to the challenge is the very slow start that the product would have due to the REMS, which would require physicians to train specifically for the installation of Probuphine. This may limit it to a niche market that doesn't provide enough revenue to justify Titan's current valuation.

The Takeaway

The FDA decision on the Probuphine NDA is generally expected to be positive due to the incredible rise in opioid abuse in the United States, and the strong safety profile that the product has built throughout the clinical development phase. The efficacy profile is less certain due to dosage uncertainties, although the biggest challenges for Titan may actually come after FDA approval as the company has to compete with the likes of Suboxone for opioid addiction treatment.

Question and Answer Session: 4/22/13

Operator

(Operator Instructions). Our first question comes from Afua Ahwoi of Goldman Sachs.

Afua Ahwoi - Goldman Sachs

Thank you. Two questions, first, on the buyback, giving you have run through the authorization you have outstanding, how should we think about on the go forward, should we expect a formal announcement or are you just going to continue to buy back, given your credit facilities give you that ability? And then second, on pricing, should we actually think about the difference with the split between reduction of discounts and actually raising ticket prices whether it's on season pass side or even at the gate prices. Thank you.

John Duffey

In terms of the buyback we have approximately as of today 140 million remaining on our board authorization for buyback and we can do incremental amount in addition to that through the credit agreement but we’re not going to disclose exactly what our plans are in terms of the remainder of the year.

Jim Reid-Anderson

To your question once we at a point where we have utilized all 114 but remains the board authorization we would then come back and make some sort of announcement but right now we will buy at our own pace. With regards to pricing we don’t give guidance as to what exactly what has led to increases in price rather all will do and say that it has come in both areas and so we did take our main-gate pricing up and we also had reduced our discounts so both will be contributing bot only happen to this but we will continue to contribute going forward as well.

Operator

Our next question is from Ian Zaffino of Oppenheimer & Co.

Ian Zaffino - Oppenheimer & Co

As far as looking at your project 500 goal, how do you get -- and maybe I was just -- plenty of times before, but give me an idea of as you look between the admissions per cap and then also in-park spend, which is going to be the bigger driver? Is it going to be the pricing side? Is it going to be the in-park spend? Where do you think you have more room to go?

Jim Reid-Anderson

I think it's a really good question Ian and much like a forward question. I can’t give you, this is the breakdown here it is but I can give you a general view as to what we believe. I think we have opportunities across many fronts and I really do believe that we’re going to see growth driven by our season pass strategy. We’re already seeing that and we anticipate continuing to see that improvement in attendance I think concurrently we will see increases because of pure pricing and reductions of discounts and that will be a major contributor for us and then I think that incrementally because we will have more people in the park whilst we might say it's a little bit pressure on the in-park spending per cap total revenue will grow and so I see all three of those areas as being huge opportunities for us going forward and I will give you an example why I think that in-park spending is a growth opportunity as well not only will we see more people in the park throughout these entire strategy but in addition as we have said we have introduced an all season dining pass which we think is a great value in a tough economy and we think that’s going to help drive our revenue forward. So I would say there are numerous opportunities but those three would be the biggest from a pure financial perspective and of course there are others that were targeting maybe at a slightly lower level.

Ian Zaffino - Oppenheimer & Co

So as you look at all your in-park spend initiatives, is it really this dining pass that's going to be the biggest driver? Or are there other opportunities? How do you rank, if you could, your initiatives? Where would let's just say dining be on that list? Where would some of the other initiatives that you have in the hopper rank on that list?

Jim Reid-Anderson

I think that they really are multiple initiatives that are ongoing, our team across the company, across parks are coming up with innovative new ideas but I think you have to remember that food represents about 50% of our in-park revenue and this program is in a place where people who may not traditionally spend were targeting those to be able to spend in our park. So I would say to you that our single biggest opportunity right now is in-park, is this all season dining but I would add that there are others including our flash pass program that we think will give us incremental revenue as well.

Operator

Our next question is from James Hardiman of Longbow Research

James Hardiman - Longbow Research

Couple of quick questions here, just want to make sure I understand the puts and takes of the calendar shift here. I realize you don't give much in the way of guidance but any guide points that you could give us with respect to the second quarter of the rest of the year would be great. I think you mentioned that half of the attendance gain, half of that $525,000 was a function of the calendar. Do you expect that to be a zero-sum shift? In other words, should I just take half of that $525,000 and back that out of my second-quarter number and basically use that as a baseline? Are there any other calendar shifts that we should be aware of over the course of the rest of the year?

Jim Reid-Anderson

Yeah in terms of the remainder of the year, there really are no significant calendar shifts for the remainder of the year. Obviously the significant impact was in the first quarter and approximately we set half of that increase that we saw was due to opening our parks earlier because of the shift in the spring break. So yes you should assume that will be a negative impact in the second quarter.

James Hardiman - Longbow Research

Great and then the second quarter last year appear to be the biggest beneficiary certainly on the attendance side from the new rides and attractions in 2012. It sounds like you guys are really bullish on the CapEx program this year. Do you expect a similar program, just given that the people that are most excited to participate in these new rides are most likely to come in the second quarter? Do we expect a similar pattern to play out this year versus last?

Jim Reid-Anderson

We don’t provide guidance on what’s going to happen in anyone quarter and we referenced on numerous calls that we try to track how we’re doing on an LTM basis because that gives you the best sense of how the business is doing. So I won't predict what will happen in the second quarter what I will say is that we continue to see very nice momentum, LTM on attendance, on revenue, on profitability and the capital line-up that we have. I really believe that 212 was the best line-up but I’m being told now and I do also believe that 2013 is going to be very better and I have to believe that our guests are now getting more and more aware of what we’re doing, we will see that as a big positive. So I won't predict for you what will happen but I will tell you that I feel pretty good about the direction we’re headed in.

James Hardiman - Longbow Research

Got it. And then last question, I don't know how much of this you can give us. Obviously you are not going to quantify the price increases, season passes versus front gate. I think you have commented in the past about how in 2012 sort of that breakeven point, right, the point at which the rational customer would go toward season passes versus the daily passes, was skewed a little bit towards season passes last year, from a relative pricing perspective. How should I think about that? If you could give us any color for 2013 -- if I know I am coming to the park a certain number of times in 2013, is it going to be more or less attractive to buy season's passes or is it pretty comparable to what was in 2012? Thanks.

Jim Reid-Anderson

Well we continue to believe that it's highly attractive to buy a season pass and I think given the numbers that John threw out earlier about what we’re seeing on the seasons pass run it would suggest that our guest believe that as well. So I think it's always a better value to be able to utilize the season pass. I think that the percentage of guest to visit who are season pass holders will increase. I hope that answers your question.

Operator

Our next question comes from Ian Corydon of B. Riley & Co

Ian Corydon - B. Riley & Co

A lot of questions have been answered but I just wanted to drill down on sponsorship licensing. You saw that tick up year over year for the first time in quite a while. I'm just wondering if we can expect that to grow and maybe if we can get an update on your initiatives to try to build on that.

Jim Reid-Anderson

It's an excellent question Ian and yeah we’re very pleased to see the trend on the corporate sponsorship side improving and I really believe that the last couple of years have all been about eliminating sponsorship deals that might have given us revenue but very little in the way of profit or cash flow and we’re now through that process. So we do anticipate some modest increases with regard to this line-item and our team, we have an excellent team that’s laser focused on this.

Operator

Our next question comes from Kevin Coyne of Goldman Sachs.

Kevin Coyne - Goldman Sachs

I just had one on season ticket sales. I was just wondering, is the strength broad-based like across most of the parks? Or, I guess, related to some of the disruption in New Jersey related to Hurricane Sandy, are you seeing perhaps more strength in your season ticket sales there because of some other amusement options being off-line?

Jim Reid-Anderson

It's a great question actually Kevin and you’re right there was some impact on some amusement options but those really were not major competitors for us. I think the really good news that I tell you is that we’re seeing growth in every single park, there is nowhere that we have not seen tremendous improvement. So it is broad-based across the board.

Operator

Our next question comes from Tim Conder of Wells Fargo

Tim Conder - Wells Fargo

Thank you. I apologize, joined the call late, we were on another overlapping call but a couple of questions, everyone. You talked about the in-park spend opportunities. Can you update us on where you are as that relates to the Water Parks themselves? Any new initiatives there this year, Jim? And then also just give us a little bit of an update as to your ability now, taking the data from your CRM and the point of sale, where you stand with that in being able to really mind that for additional in-park spending opportunities.

Jim Reid-Anderson

Very good set of questions there, Tim, I think the water-parks themselves I believe are in very good shape, you may remember that park way through the year last year we rolled out the low-queue option, our flash pass in the water parks and this will be the first year where we have a full year in the water parks and I think that is going to be very powerful for us. I would also add that in pretty much every water-park not only have we got brand new attractions to pull people in so we have got new water-slides new attractions in every single water-park. But we have also changed several of the retailing and food options so we have got new dining menus and we also have several new restaurants. So we’re targeting several opportunities in our water-parks and I think my belief is that given that plus pricing increases we have taken, we should be in pretty good shape for this year. The second question was around CRM and I know this has come up on other calls but that we have listened to and I have to tell you that we’re in really incredible shape and have been for a while. I think I mentioned that one of the beauties of Six Flags is abundance of data that existed. We’re right up-to-date in terms of IT. So we know exactly what we’re selling pretty much in every park at every retail outlet or dining operation on an ongoing basis and so we’re already mining that and we will continue to do so going forward. John do you want to add to that?

John Duffey

I would just add on Jim’s comment that I think we’re in great shape as it relates to our systems and particularly around CRM and we are investing dollars every year to enhance our CRM. The good news is that we don’t have any significant investments that need to be made.

Jim Reid-Anderson

We made big investments over the last few years. I think the other piece that comes up a lot Tim and I want to reference is dynamic pricing. Again on that front we’re in a very good place, we have actually utilized dynamic pricing at various points and we continue to a really good example of that would be price set at last year. We were able to utilize that on certain days that are more popular than others to be able to spread attendance. Overall from an IT, CRM perspective I feel like we’re in good shape but we will always keep an eye to see if there is anything else that we can do to make us stronger.

Tim Conder - Wells Fargo

John, I apologize. Again, I joined the call late. Can you just give me a quote on your season passes at this point year over year?

John Duffey

In terms of the season passes we don’t disclose the actual dollar amount of the sales or the attendance mix. But I always refer back to the differed revenue which was up 41%.

Jim Reid-Anderson

So it's in the press release Tim and it shows the increase of $27 million or 41% compared to March of 2012.

Tim Conder - Wells Fargo

Okay, and then last year on the season passes roughly 44% of your attendance was season pass. Correct?

John Duffey

That’s correct for the entire year.

Tim Conder - Wells Fargo

And you obviously expect that to go up this year?

Jim Reid-Anderson

We do.

Operator

(Operator Instructions). Our next question comes from Joel Simkins from Credit Suisse.

Joel Simkins - Credit Suisse

A couple of quick questions here. The first one is, you did recently announced this weather guarantee for the New England Park. I would like to get some more color on that. Obviously, you guys were pretty pleased with the pass. The progress on season pass sales year to date. Can you give us a sense of what your advertising mix has been this year versus last year and how you plan to shift that, perhaps, as we head into the heart of the season?

Jim Reid-Anderson

With regard to the weather guarantee, we have been testing this option in New England and I think that the real benefit is guest perception and what we have found is that people really appreciate the fact that you would offer to allow them to come back on another day if the weather is bad for a couple of hours or more and so we’re testing it in New England and obviously the park hasn’t been opened that long but the initial reaction is very positive and as I said it has very little negative financial impact but huge guest perception upside and I would rather give you more of a flavor for this at the end of the year once we have had a full year task but my view would be that this is something we would probably roll-out across all of our parks.

Joel Simkins - Credit Suisse

Okay, and again the question following up on your advertising?

Jim Reid-Anderson

The advertising mix, can I just clarify the question is it timing, the timing of the spend or the type of spend?

Joel Simkins - Credit Suisse

Really more of the type of spend.

Jim Reid-Anderson

The type of spend, it mimics very closely what we did last year so successfully. So you may remember Joel that historically the company would have spent the bulk of its money on TV advertising and that would be national TV advertising and the spend shift that has taken place in the last 1.5, 2 years has really been to ensure that we not only have TV advertising but that TV advertising is more local in nature, the local channels but then we have also radically increased our spending online but we have gone back to utilizing billboards, we have really pushed up our spend on radio and then finally with our relationship with one of our partners Coca Cola, we have Cinema advertising and the combination of all of those really has resulted in a much higher impact spend than we had previously and I think that’s part of the reason that we’re such success with regard to our capital story because historically people may not have been aware of what we’re doing now they know because we’re telling local people within 300 miles of our parks what’s going on at their local park.

Operator

At this time there are no other questions.

Jim Reid-Anderson

Okay thanks Marian. We really appreciate all of you joining our call today and I want to say that I hope you can take the time to visit at least one of our beautiful parks to season in order to experience all that we have to offer. Meanwhile I do want to make sure that you know that you can rest assured that our team is focused on delighting our guests and driving incremental shareholder value in the coming quarters and years ahead. Take care and I hope to see you soon.

Operator

This does conclude today’s conference call. You may disconnect your phones at this time.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

KBLB is a stock;whether on the OTC board or the NYSE.

As with any stock,there will be certain variables to consider,such as confidence,a person's financial situation,whether or not other stocks are doing well that an individual has invested in;the list is endless.

A vast majority of the stock markets companies PPS elevate when positive news is generated but there are the others that are exceptions to the rule.

I believe in the potential of this stock but do not have my head in the clouds.

Seeing the company for what it is currently,at developmental stage,I ask myself,how much can I realistically expect from KBLB at this point in time?

Sure, time had passed,decisions were made and certain ties have been severed.
Chalk it up to the greater good.

If a person doesn't make a mistake,what is there to truly learn from?
The point is to prevent the same occurrences from repeatedly happening.

My curiosity with Kim lies not in his innate intelligence,as he is definitely brilliant but in where he envisions on taking KBLB.......

I believe we will have some answers revealed in the foreseeable future.

This,I remind myself,as i'd rather know that a deal took a little longer than expected and was properly executed,than to be rushed for the sake of becoming newsworthy,shorting both the company and its stockholders.

Hello wishingwell4u and welcome. :- )

As this company is still in the development stage of something potentially significant,the government has agreed to collaborate with this particular company. In my estimation,it's a good thing.

I truly hope that the company will provide updates from time to time,as a vast majority of their work will probably be covered under a non-disclosure agreement.

One thing's for sure; potential demand for a product of this nature is one of the reasons i invested and will continue to for some time.

Hello Sharky55423.

I always suggest that a person do their due diligence,when choosing a particular stock.

This company has had its moments but I feel they are definitely on the track to bigger and brighter things.

Welcome LasNubes. :- )

1st quarter earnings this Thursday- 4/25/13.

Welcome hassified.

It's always a pleasure to know that another stockholder has joined the ranks of KBLB.

Correction= 930k +

Price is beginning to climb.......Zohydro decision any day now.

SmurfVA,

The "run-up" is due to happen,as the approval date gets closer and closer.

As the next several days go by, I would expect the price per share to increase,due in part to reluctancy to sell shares.

If Probuphine is approved,this could be the start of something wonderful;for both the company and its stockholders alike.

920,057 volume.....1.95 price per share............

Not bad at all.